Samba-AC: A Randomized, Open-Label, Cross-Over Study to Investigate the PK and PD Profiles of Dance 501 (Human Insulin Inhalation Solution and Inhaler) in Healthy Subjects and Non-Diabetic Subjects With Mild to Moderate Asthma or COPD

Trial Profile

Samba-AC: A Randomized, Open-Label, Cross-Over Study to Investigate the PK and PD Profiles of Dance 501 (Human Insulin Inhalation Solution and Inhaler) in Healthy Subjects and Non-Diabetic Subjects With Mild to Moderate Asthma or COPD

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 May 2018

At a glance

  • Drugs Insulin (Primary) ; Insulin lispro
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Pharmacokinetics
  • Acronyms Samba-AC
  • Sponsors Dance Biopharm
  • Most Recent Events

    • 01 May 2018 Planned End Date changed from 17 Jul 2018 to 30 Aug 2018.
    • 01 May 2018 Planned primary completion date changed from 31 May 2018 to 30 Jul 2018.
    • 01 May 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top